GlobeNewswire

BioVie Presents New Biomarker Data from the ADDRESS-LC Trial of Bezisterim in Long COVID at the NIH RECOVER-TLC Third Annual Workshop
09/11/2026
New findings from the Phase 2 ADDRESS-LC trial suggest two distinct biomarker-defined Long COVID endotypes 1 associated with different patient responses to bezisterim treatment. Patients with a high-inflammatory [...]
R1 and Ascension Extend Partnership Through 2037 Leveraging Phare OS to Advance a Technology-First Revenue Cycle
09/11/2026
Long-term agreement supports Ascension’s efforts to simplify the financial experience for patients, reduce administrative demands, and give care teams more time to focus on those they serve CHICAGO, Nov. 09, 2026 (GLOBE [...]
Mereo BioPharma Reports Third Quarter 2026 Financial Results
09/11/2026
Ongoing regulatory interactions in collaboration with Ultragenyx on potential path forward for setrusumab in osteogenesis imperfecta (OI) Ongoing FDA interactions in collaboration with Sentynl Therapeutics to refine [...]
Achieve Life Sciences Becomes AchieveRx, The Quit Company, and Will Trade Under the Ticker QUIT
09/11/2026
New name and ticker reflect a mission-driven company with one purpose: developing medicine for people who want to quit smoking or vaping. If approved, cytisinicline would be the first new medicine approved by the FDA [...]
Eos SENOLYTIX’s PTC-2105 Reduced Semaglutide-Associated Lean-Mass Loss in Aged Mice: Data to Be Presented at 19th Sarcopenia, Cachexia & Wasting Disorders International Conference
09/11/2026
Data to highlight PTC-2105’s attenuation of terminal lean-mass decline and semaglutide-associated lean-mass loss in aged mice PTC-2105 is Eos’s lead clinical candidate in development for elderly patients with Sarcopenia [...]
DeepLife and 3billion partner to discover small-molecule therapeutics against genetic modifier targets across multiple diseases
09/11/2026
The collaboration combines DeepLife's AI virtual-cell platform, TwinCell, with 3billion's genomics and AI-driven medicinal chemistry technology, to create an end-to-end engine for discovering genetic modifier targets [...]
Codexis Advances ECO Synthesis Toward Adoption Readiness with Quality at Scale and Expanded siRNA Manufacturing Capabilities
09/11/2026
Data shared at TIDES Europe demonstrates consistent and robust platform performance while delivering high product quality at scale, alongside new platform capabilities in targeting functionality and initial results [...]
Biodesix to Showcase MRD Strategy at the Association for Molecular Pathology (AMP) 2026 Annual Meeting
09/11/2026
New data highlighting proprietary bioinformatics, ultrasensitive molecular detection, and collaborations with Bio-Rad Laboratories and Thermo Fisher Scientific to advance scalable MRD solutions for clinical laboratories [...]
Edesa Biotech Announces Agreement with KYORIN Pharmaceutical to Develop and Commercialize Paridiprubart in Japan
09/11/2026
Deal valued at more than $140 million in upfront and potential milestone payments, plus double-digit royalties. Kyorin obtains exclusive rights to develop and commercialize paridiprubart, an anti-TLR4 monoclonal [...]
Epitopea Announces First Patient Dosed in OVACT Phase 1/1b Clinical Trial of CryptiVax™-1001 in Advanced High-Grade Serous Ovarian Cancer
09/11/2026
CAMBRIDGE, UK and MONTREAL, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Epitopea, a clinical-stage, biotech company developing off-the-shelf, durable RNA-based cancer vaccines, announced today that the first patient has been [...]
Epitopea annonce l'administration de la première dose à une patiente dans le cadre de l'essai clinique OVACT de phase 1/1b portant sur le CryptiVaxTM-1001 dans le cancer de l'ovaire séreux de haut grade avancé
09/11/2026
CAMBRIDGE, Royaume-Uni et MONTRÉAL, 09 nov. 2026 (GLOBE NEWSWIRE) -- Epitopea, une société de biotechnologie au stade clinique développant des vaccins anticancéreux prêts à l’emploi et durables à base d’ARN, a annoncé [...]
Nxera’s President & CEO to Participate in a ‘Fireside Chat’ at the Jefferies London Healthcare Conference 2026
09/11/2026
Tokyo, Japan and Cambridge, UK, 9 November 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces its President & CEO, Chris Cargill, will participate in a ‘Fireside Chat’ at the Jefferies [...]
Transactions in connection with and conclusion of share buy-back program
09/11/2026
Company announcement no. 45 - 26 09 November 2026 Transactions in connection with and conclusion of share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as [...]
iDEL Therapeutics Enters Global Research Collaboration with Daiichi Sankyo to Develop Multi-Drug Conjugate with Targeted Cytosolic Delivery into Solid Tumor Cells
09/11/2026
— Collaboration’s objective is to evaluate the potential of a cancer therapeutic by using iDEL’s unique shuttle technology platform — Dortmund, Germany, November 09, 2026 — iDEL Therapeutics today announced that it has [...]
Oculis to Host In-Person and Virtual R&D Day: Advancing a Differentiated Late-Stage Development Pipeline
09/11/2026
ZUG, Switzerland, November 9, 2026 -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations in neuro-ophthalmology and ophthalmology, today [...]
Oculis to Host In-Person and Virtual R&D Day: Advancing a Differentiated Late-Stage Development Pipeline
09/11/2026
ZUG, Switzerland, November 9, 2026 -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations in neuro-ophthalmology and ophthalmology, today [...]
GENFIT Highlights Data from Clinical Studies of Nangibotide, Supporting Its Advancement into ACLF with Phase 2 Data Expected in 2027
09/11/2026
Comprehensive clinical and scientific data supporting Phase 2 development of nangibotide in ACLF unveiled to leading experts during AASLD The Liver Meeting® Strong biological rationale in ACLF: TREM-1 modulation is [...]
GENFIT présente les données issues des études cliniques de nangibotide soutenant la poursuite de son développement dans l’ACLF. Résultats de phase 2 attendus en 2027
09/11/2026
Un ensemble complet de données cliniques et scientifiques solides soutenant le développement de Phase 2 de nangibotide dans l’ACLF présenté aux experts internationaux lors du congrès AASLD The Liver Meeting®. Un [...]
Essential Pharma and Nordmark announce new partnership and UK availability of Norzyme® (pancreas powder) 25,000 gastro-resistant capsules for pancreatic exocrine insufficiency
09/11/2026
Partnership brings together decades of pancreatin experience at Nordmark and Essential Pharma Norzyme ® (pancreas powder) 25,000 gastro-resistant capsules, a Nordmark medicine, has received its UK marketing [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum